apatinib + camrelizumab + capecitabine

This therapeutic regimen is a triple combination therapy consisting of apatinib mesylate, camrelizumab, and metronomic capecitabine, currently being investigated by Zhejiang University for the treatment of advanced pancreatic adenocarcinoma. Apatinib is a small-molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor 2 (VEGFR-2), thereby inhibiting tumor angiogenesis and potentially normalizing tumor vasculature. Camrelizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by binding to the programmed cell death protein 1 (PD-1) receptor, which restores the anti-tumor activity of T-cells. Capecitabine is an orally administered fluoropyrimidine carbamate that serves as a cytotoxic prodrug of 5-fluorouracil (5-FU). In this specific protocol, capecitabine is administered in a metronomic fashion (low-dose, frequent administration) to leverage its potential anti-angiogenic and immunomodulatory properties alongside its direct cytotoxic effects. The combination aims to overcome the highly immunosuppressive and hypovascular microenvironment characteristic of pancreatic cancer.

Brand names

AitanAiRuiKaXeloda

Other names

Metronomic capecitabine + camrelizumab + apatinib mesylateApatinib Mesylate TabletsCamrelizumabMetronomic capecitabine